|
|
|
|
||
Re: "Merck was knocking at their door" EXCERP ON RSVXXXXXXX Correct me if wrong...but NVAX DID NOT USE MATRIX M ADJUVANT IN THE RSV TRIAL xxxxxxx in 2019, Nasdaq threatened to delist the company after its stock fell below $1 for more than 30 days in a row. To reduce operating costs and stay afloat, Novavax sold two manufacturing plants and reduced its staff to 166. ☆☆☆☆☆☆☆ This followed the Phase III failure of the company's RSV vaccine. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
206017 | Re: "Merck was knocking at their door" EXCERP ON RSV | evsworld | 1 | 3/21/2023 11:15:47 AM |